Member Info for Divvyup

Last year, over half of the trade finance applications were rejected by banks simply because they lacked the data needed.

https://www.thestar.com/opinion/contributors/2022/04/11/russian-invasion-of-ukraine-threatens-the-global-food-supply.html
looking forward to SYME with added IOT.
ATB

Syme Non-executive Director
Speaker at Webinar. Wednesday, April 13, 2022 | 11:00 a.m. ET
https://aite-novarica.com/webinar/open-banking-readiness-european-banks
ATB

Been following Syme for some time and holding.
My opinions only, DYOR
1) Ending June/July (most) ERP /IOT will be in place to bridge capitalisation compliance standards. Further tuning of accountancy practice with comprehensive data streams Q3.
2) Aug: Existing Share Loans structure tidy up pending CAP.
Board views on IM vary, however I`m satisfied that the initial IM will be accomplished via a hands-on method rather than utilizing the Syme engine model. More human resources will be required to start IM`s rolling. (I'm keeping an eye out for recruitment within the group).
There are over 2500 fintech’s based in the Uk an indication that this is an exciting and highly competitive marketplace. Most disruptors are hampered by regulation, but when funding establishment`s continue to move towards smart contracts via Block chain the momentum for change is strong.
Looking forward to the business strategy goal report due June 2022.
Enjoying the Journey.
ATB.

Beg to differ with some. (no offence intended)
Not just Covid guys, it’s a T cell trigger for bashing current or new virus variants.
Diabetes is only one of many Immunosuppressants. Eg Methotrexate treatment of arthritis.

The objectives of St Marys trials are akin, immunodeficiency / T2DM (T cell), collaborator AstraZeneca.
Perhaps the logical approach is. Would you go for transplant trials without inside knowledge from AZ? …That must tell you something about risk and reward from previous trials.

I`m not in favour rushing through a sale until the full picture emerges especially when others see potential in adjacent fields. Timing is key and IMO now is not the time due to timescale of Peer review/independent adjudication by Sept 2022. It`s looking good but nothing beats hard facts.

IMHO We would have had investment news on inclusion within the St Marys trial.

It is hard to have patience, but as interest grows, I hope to see further spin off trials which will in turn will have a positive effect and sure up the SP for vela and many others under the AZD1656 umbrella.
ATB

AZD1656 Transplantation with Diabetes
Re Posted for those that missed.
https://clinicaltrials.gov/ct2/show/NCT05216172?term=AZD1656&draw=2&rank=1
At the Recruitment stage.

Will ADZ1656 become a catalyst for T2DM and resulting immunosuppression treatments?
The interest and commitment by Queen Mary University of London should give investors some confidence.
If successful, this should add value just by association alone.
Personal timetable Q3/Q4 for tangible news with SGS.
ATB

Dated but still a great little article about Supply chain finance.
https://www.tradefinanceglobal.com/posts/from-mesopotamia-to-artificial-intelligence-ai-the-evolution-of-supply-chain-finance/

Although not hitting headlines the ICC along with various invested parties are pushing hard for clarity of supply trade finance standards with added zest, much needed in these uncertain times.
For those new to Supplyme take note of the last section. The developing platform for inventory capitalisation by SYME fits the criteria like a glove.
I’ve been here for a while enjoying the journey and still KTF .
DYOR
ATB

https://news.sky.com/story/covid-19-deltacron-identified-as-new-variant-how-fast-is-it-spreading-and-should-we-be-worried-12563165

Peak any info on this guy from chaps at the other place.
Saad Karim Leghari : Lead Cloud Solution Architect
https://pk.linkedin.com/in/saadkarimleghari
Interesting as Azure is on the list of to do`s for Q2.
Noted no 3 on list : Develop Multi Cloud Architecture for SYME
Confirmation that this is our SYME would be appreciated.
ATB

IMO: If workable I’d rather see a license and royalty structure with regular income streams than a big hit at this early stage.

https://clinicaltrials.gov/ct2/show/NCT05216172?term=AZD1656&draw=2&rank=1

Great RNS with key enhancements over current treatments.
1) A safer and more effective alternative to immunomodulatory treatments.
2) Efficacy is unlikely to be compromised in treating disease caused by new virus variants.

ATB

https://www.computerweekly.com/news/252513093/UK-fintech-investment-sees-sevenfold-increase-in-a-year
Q2 approaches IM approaches?

Corus A-Z…. AZ Pay Me My Money Down.
https://www.youtube.com/watch?v=BGuVPq7cxi0

ATB

Precious metals flying....re Russia ..Ukraine
Feel for those fleeing.

___|___|___
___|___|___
| |

___|___|___
___|___|___
. | |

___|___|___
___|___|___
| |

___|___|___
___|___|___
| |

___|___|___
___|___|___
| |

Volvie: Awe don’t say that, my golden pancakes flat enough.
My investments in SYME has been like watching the gold rush 49ers
The real winners were those that sold shovels.
Unfortunately, the price of shovels has temporarily crashed :))
ATB

Most notable is the recent SAP acquiring a controlling stake in the capital management company Taulia should not be overlooked as fintechs reach to bridge the gap between capital and client.
Quote: Enrico Camerinelli
“Banks should set up tight partnerships with fintech vendors that follow the strategy of building a platform friendly to their banking partners. And fintech vendors should develop solutions that generate real business opportunities for banks while ensuring that SCF solutions reduce both operational costs and credit risks for bank adopters”.

Naturally API follows suit, something Smaller banks that do not have the budget and rely on fintech partners to deliver API-based digital solutions to and from their customers.

I strongly believe syme evaluated the platform last summer which highlighted a weak area around live supply chain data.
Jim Coyle’s appointment may well have been to clarify and hone the current Syme model with an improved user-friendly structure or at least that’s what I’m hoping for with his knowledge and corporate networking.
A bank/funder friendly system is now a must not an add on.

Fully integrated ERP & partial TMS platform is noted for Q2 2022 as per June 2021 RNS.

It would be good to have a progress report on ERP /IOT/TMS perhaps March or early April.
Am I asking to much….
ATB

https://aite-novarica.com/insights/blogs?author_select=11268
ATB